

Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update) Guideline Committee Interests Register

Register last updated: 9th March 2023

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------|----------------|------------------|---|---|-------------------|-----------------|---|
| Dr Jeremy Isaacs | Chair | Direct Financial | Consultant Neurologist, St George's University Hospitals NHS Foundation Trust | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and Participate Agreed by: Guideline lead in February 2023 Rationale: Salaried employment in the NHS. |
| Dr Jeremy Isaacs | Chair | Direct Financial | Honorary Consultant Neurologist, Kingston Hospital NHS Foundation Trust | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline |
| Dr Jeremy Isaacs | Chair | Direct | Honorary Senior Lecturer, St George's, University of London | Interest arose more | February 2023 | Ongoing | Declare and participate. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------|----------------|------------------|--|-----------------------------------|-------------------|-----------------|--|
| | | Financial | | than 12 months before appointment | | | <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline as related to Neurology.</p> |
| Dr Jeremy Isaacs | Chair | Direct Financial | Funding for attendance at the Clinical Trials in Alzheimer's Disease conference, San Francisco (registration, travel and accommodation) from Roche Products Ltd UK | 28/11/22 | February 2023 | 03/12/22 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline</p> |
| Dr Jeremy Isaacs | Chair | Direct Financial | Payment to my institution for consultancy work for Roche on Alzheimer's disease treatments | 05/10/22 | February 2023 | 15/12/22 | <p>Declare and participate.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------|----------------|---------------------|---|--|-------------------|-----------------|--|
| | | | | | | | <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline</p> |
| Dr Jeremy Isaacs | Chair | Direct Financial | Clinical Director, NHS England (London) Dementia Clinical Network | Interest arose more than 12 months before appointment | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline</p> |
| Dr Jeremy Isaacs | Chair | Direct Financial | Specialty Research Lead, Neurological Disorders and DeNDRoN, South London Clinical Research Network | Interest arose more than 12 months before appointment | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|--|---|-------------------|-----------------|--|
| | | | | | | | Rationale: Not specific to the guideline |
| Dr Jeremy Isaacs | Chair | Non-financial professional and personal | Director and Trustee, British Neuropsychiatry Association | May 2022 | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline</p> |
| Mr Feras Al Jaafari | Topic Advisor | Direct Financial | Consultant Urological Surgeon, NHS Fife, Victoria Hospital, Kirkcaldy, Scotland | Interest arose more than 12 months before appointment | February 2023 | Ongoing | <p>Declare and Participate</p> <p>Agreed by: Guideline lead in February 2023</p> <p>Rationale: Salaried employment in the NHS.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Direct Financial | Proctor for Greenlight laser prostatectomy and Rezum. I have proctored colleagues from all over the UK in both procedures. | Interest arose more than 12 months | November 2022 | Ongoing | Declare and participate. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|------------------|---|------------------------------------|-------------------|-----------------|--|
| | | | My visit expenses are fully covered by industry (travel, accommodation) and I do receive honorarium for the time spent teaching (I do take a day off from NHS to do that) | before appointment | | | <p>Agreed by: Guideline lead and NICE at recruitment.</p> <p>Rationale: Will not be able to make recommendations relating to Greenlight laser prostatectomy and Rezum, should this arise. However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Direct Financial | Private practice (Spire Edinburgh, Nuffield Edinburgh). This is 10-15% of my overall practice. I see a variety of patients (40% BPH, 60% | Interest arose more than 12 months | November 2022 | Ongoing | Declare and participate. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|------------------|--|--------------------|-------------------|-----------------|---|
| | | | stones, peno-scrotal etc). No financial interest in the hospitals where I do private practice. | before appointment | | | <p>Agreed by: Guideline lead and NICE at recruitment.</p> <p>Rationale: This private practice is not a conflict due to limited weekly work and no financial interest in the clinic.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Direct Financial | Consultancy fees for supervising/contributing to publication: Burt G, Springate C, Martin A, Woodward E, Zantek P, Al Jaafari F, Muir G, Misrai V. The Efficacy and Safety of Laser and Electrosurgical Transurethral Procedures for the Treatment of BPO in High-Risk Patients: A Systematic Review. Res Rep Urol. 2022 Jun 17;14:247-257. doi: 10.2147/RRU.S361956. PMID: 35757198; PMCID: PMC9215288. | 2022 | November 2022 | 2022 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Will not to be able to make recommendations relating to Laser and Electrosurgical Transurethral Procedures, should this arise.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|--|----------------|-------------------|-----------------|--|
| | | | | | | | However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this. |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | BAUS (British Association of Urological Surgeons) Endourology Executive committee member – elected | 2022 | November 2022 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead and NICE at recruitment.</p> <p>Rationale: Does not require withdrawing from the committee</p> |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | GIRFT BPH working group. Co-authored the BPH GIRFT document. | 2021 | November 2022 | Ongoing | Declare and participate. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|---|----------------|-------------------|-----------------|---|
| | | | | | | | <p>Agreed by: Guideline lead and NICE at recruitment.</p> <p>Rationale: Does not require withdrawing from the committee. Getting It Right First Time (GIRFT) is a national programme designed to improve medical care within the NHS.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | Trail, M., Hindley, R. G., Al Jaafari, F. (2021). Contemporary surgical management of benign prostatic obstruction: does there remain a place in the toolbox for TURP? Journal of Clinical Urology. https://doi.org/10.1177/20514158211010646 | 2021 | November 2022 | 2021 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|--|----------------|-------------------|-----------------|---|
| | | | | | | | <p>Rationale: Will not be able to make recommendations relating to TURP, should this arise.</p> <p>However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | Designated as Expert user of Rezum and Greenlight Laser therapies by Boston Scientific | 2022 | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in March 2023.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|---|----------------|-------------------|-----------------|--|
| | | | | | | | <p>Rationale: Will not to be able to make recommendations relating to Rezum or Greenlight laser therapy, should this arise. However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | Guest Editor for the BPH supplement of Urology News (will be published in March 2023) | 2023 | February 2023 | 2023 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: If published work expressed strong</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|--|---|-------------------|-----------------|---|
| | | | | | | | opinions, will need to withdraw from discussions relating to these topics, if this arises. |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | Expert Advisor to The National Institute for Health and Care Excellence (NICE) on Medical technologies guidance (MTG74) GreenLight XPS for treating benign prostatic hyperplasia | Interest arose more than 12 months before appointment | February 2023 | November 2022 | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Does not require withdrawing from the committee |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | BPH Section Editor – Journal of Clinical Urology – SAGE (Official BAUS Journal) | 2022 | February 2023 | 2022 | Declare and participate. Agreed by: Guideline lead in February 2023. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|---|----------------|-------------------|-----------------|--|
| | | | | | | | Rationale: If published work expressed strong opinions, will need to withdraw from discussions relating to these topics, if this arises. |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | BAUS Annual meeting. Speaker – 3 invited talks: • Talk on the management of severe haematuria • Talk on Shared decision making in BPH surgery • Talk on primary urteroscopy – our personal experience (GIRFT session) | 2022 | February 2023 | 2022 | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Does not require withdrawing from the committee |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | BAUS Annual meeting. Tutor: BPH Hands-on-Training – Greenlight laser | 2022 | February 2023 | 2022 | Declare and participate. Agreed by: Guideline lead in February 2023. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|--|----------------|-------------------|-----------------|---|
| | | | | | | | <p>Rationale: Will not to be able to make recommendations relating to Greenlight laser, should this arise. However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | BAUS BPH Annual meeting. Speaker: Greenlight laser | 2021 | February 2023 | 2021 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Will not to be able to make</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|---|--|----------------|-------------------|-----------------|--|
| | | | | | | | <p>recommendations relating to Greenlight laser, should this arise. However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this.</p> |
| Mr Feras Al Jaafari | Topic Advisor | Non-financial professional and personal | <p>Trail, M., Good, D., Clyde, D., Brodie, K., Leung, S., Simpson, H., Kata, S. G., Tsafrakidis, P., Chapman, R. A., Mitchell, I., Janjua, K., & Al Jaafari, F. (2021). Day Case GreenLight Laser Photoselective Vaporisation of the Prostate (GL-PVP): Evaluation of Outcomes from a District General Hospital Experience of 538 Cases. Journal of Endoluminal Endourology,</p> | 2021 | February 2023 | 2021 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Will not be able to make</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------|-------------------|--|----------------|-------------------|-----------------|--|
| | | | 4(3), e8-e16. https://doi.org/10.22374/jel-eu.v4i3.128 | | | | recommendations relating to GreenLight Laser Photoselective Vaporisation of the Prostate (GL-PVP), should this arise. However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this. |
| Mr Feras Al Jaafari | Topic Advisor | Indirect interest | Chair – BPH session at the Royal Society of Medicine | 2022 | February 2023 | 2022 | Declare and participate. Agreed by: Guideline lead in February 2023. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|-----------------|----------------|------------------|--|---|-------------------|-----------------|--|
| | | | | | | | Rationale: Does not require withdrawing from the committee |
| Robin Ward | Lay member | | No interests declared | | | | |
| Stephen Habgood | Lay member | Direct Financial | I am Director of a Community Interest Company – ‘Making Families Count’. This group delivers workshops to NHS managers about involving families in the investigation into such events as suicides and homicides, for which I am paid expenses and an attendance fee. | Interest arose more than 12 months before appointment | November 2022 | Ongoing | Declare and participate. Agreed by: Guideline lead and NICE at recruitment. Rationale: Not specific to the guideline |
| Stephen Habgood | Lay member | Direct Financial | Assistant Priest – Parish of Eccleshall in the Diocese of Lichfield This is a non-stipendiary role but I am paid fees for some services, such as funerals or weddings. | Interest arose more than 12 months before appointment | November 2022 | Ongoing | Declare and participate. Agreed by: Guideline lead and NICE at recruitment. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|-----------------|----------------|------------------|---|---|-------------------|-----------------|---|
| | | | | | | | Rationale: Not specific to the guideline |
| Stephen Habgood | Lay member | Direct Financial | National Institute for Health Research. I am a Lay committee member for the Programme Grants for Applied Research committee, for which I am paid a review fee and for meeting attendance. | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline |
| Stephen Habgood | Lay member | Direct Financial | National Institute for Health Research. Since 2017 I have undertaken numerous academic reviews as a lay advisor. For these I am paid a lay review fee. | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|-----------------|----------------|---|--|---|-------------------|-----------------|--|
| Stephen Habgood | Lay member | Direct Financial | Berkshire Mental Health NHS Trust. I deliver suicide prevention sessions as part of their suicide prevention training programme, for which I am paid an attendance fee | Interest arose more than 12 months before appointment | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline</p> |
| Stephen Habgood | Lay member | Non-financial professional and personal | Chairman of the national charity PAPHYRUS | Interest arose more than 12 months before appointment | November 2022 | June 2019 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead and NICE at recruitment.</p> <p>Rationale: Not specific to the guideline, PAPHYRUS is a suicide prevention charity.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|-----------------|----------------|---|--|---|-------------------|-----------------|---|
| Stephen Habgood | Lay member | Non-financial professional and personal | Lay member of the NICE Medical Technologies Advisory Committee. | Interest arose more than 12 months before appointment | February 2023 | November 2022 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline</p> |
| Stephen Habgood | Lay member | Non-financial professional and personal | Lay member of the Midlands Therapeutics Review and Advisory Committee (MTRAC). MTRAC is a prescribing and commissioning advice committee funded by subscriptions from Clinical Commissioning Groups (CCGs) in the West Midlands. | Interest arose more than 12 months before appointment | February 2023 | October 2021 | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Interest arose and ended more than 12 months before recruitment.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|------------------|---|--|---|-------------------|-----------------|---|
| Stephen Habgood | Lay member | Non-financial professional and personal | Advisor to the Board of Trustees of the Charity Survivors of Bereavement by Suicide. I advised the Board on issues of governance and engagement and support to those recently bereaved by suicide. | Interest arose more than 12 months before appointment | February 2023 | July 2020 | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline |
| Dr Sandeep Randhawa | Committee member | Direct Financial | General Practitioner, Modality Partnership & Limited Liability Partnership | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and Participate Agreed by: Guideline lead in February 2023 Rationale: Salaried employment in the NHS. |
| Dr Sandeep Randhawa | Committee member | Direct Financial | Partner, Modality Partnership & Limited Liability Partnership | Interest arose more than 12 months before appointment | November 2022 | Ongoing | Declare and participate. Agreed by: Guideline lead and |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------------------|------------------|------------------|--|---|-------------------|-----------------|--|
| | | | | | | | NICE at recruitment. Rationale: Not specific to the guideline |
| Dr Sandeep Randhawa | Committee member | Direct Financial | Senior Clinical Tutor University of Birmingham | Interest arose more than 12 months before appointment | November 2022 | Ongoing | Declare and participate. Agreed by: Guideline lead and NICE at recruitment. Rationale: Not specific to the guideline, teaching related to PGCert. |
| Dr Subrahmanyam Radhakrishna | Committee member | Direct Financial | Consultant Anaesthetists University Hospital Coventry and Warwickshire | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and Participate Agreed by: Guideline lead in February 2023 |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------------------|------------------|------------------|--|---|-------------------|-----------------|---|
| | | | | | | | Rationale: Salaried employment in the NHS. |
| Dr Subrahmanyam Radhakrishna | Committee member | Direct Financial | Private practice in BMI Meriden Hospital. Do only ENT, Ophthalmology and rarely other specialties like Gynaecology and orthopaedics. Do not undertake private Urology cases. | Interest arose more than 12 months before appointment | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Not specific to the guideline.</p> |
| Dr Subrahmanyam Radhakrishna | Committee member | Direct Financial | Invited speaker and workshop tutor nationally and internationally on airway related topics. No urology connection. Receive no funding for these lectures but the organizers cover my travel and accommodation expenses for each of the invited lectures. | Interest arose more than 12 months before appointment | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------------------|------------------|---|--|---|-------------------|-----------------|--|
| | | | | | | | Rationale: Not specific to the guideline. |
| Dr Subrahmanyam Radhakrishna | Committee member | Direct Financial | Expert advisor to Medicines Health Products regulatory agency (MHRA) on anaesthesia-related products that are undergoing clinical trial. I advise on the safety aspect of the equipment. My work does not involve any equipment that has any relationship to any urological products or applications. MHRA pays a fixed £800/- for each evaluation | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline. |
| Dr Subrahmanyam Radhakrishna | Committee member | Non-financial professional and personal | Member of Cochrane anaesthesia review group for Systematic reviews of anaesthesia related topics- all airway related- no financial incentives to declare. | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------------------|------------------|---|--|---|-------------------|-----------------|--|
| Dr Subrahmanyam Radhakrishna | Committee member | Non-financial professional and personal | Elected Board Member association of Anaesthetists | September 2022 | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline. |
| Dr Subrahmanyam Radhakrishna | Committee member | Non-financial professional and personal | Member of BMA, BAPIO (British association of Physicians of Indian Origin), BAOIA (British association of Indian anaesthetists) and receive no financial remuneration. These are trade unions working for equality and diversity. | Interest arose more than 12 months before appointment | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline. |
| Dr Subrahmanyam Radhakrishna | Committee member | Non-financial professional and personal | Member of the Local committee for clinical excellence awards for West Midlands region. | Interest arose more than 12 months | February 2023 | Ongoing | Declare and participate. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|------------------|---|--------------------|-------------------|-----------------|--|
| | | | | before appointment | | | Agreed by: Guideline lead in February 2023. Rationale: Not specific to the guideline. |
| Marcus Drake | Committee member | Direct Financial | Professor of Neurological Urology, Imperial College, London | 2022 | February 2023 | Ongoing | Declare and Participate Agreed by: Guideline lead in February 2023 Rationale: Salaried employment at an academic institution. |
| Marcus Drake | Committee member | Direct Financial | Director of "Dr MJ Drake limited". Income from medicolegal and expert witness work and ad hoc speaker engagements; work on 3 occasions paid by Astellas, who make | 2022 | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|---|---|----------------|-------------------|-----------------|--|
| | | | medications to treat overactive bladder: <ul style="list-style-type: none"> • Talk on Overactive bladder at Urinary Incontinence Annual Conference, Cartagena paid for by Astellas. • Webinar on LUTS for Brazilian urologists, paid for by Astellas. • Paid Expert witness in an overactive bladder treatment patent case for Astellas. | | | | Rationale: May need to withdraw from making recommendations if Astellas products considered for inclusion, if that arises |
| Marcus Drake | Committee member | Non-financial professional and personal | Trustee of the International Continence Society (UK charity) | 2022 | November 2022 | Ongoing | Declare and participate. Agreed by: Guideline lead and NICE at recruitment. Rationale: Trustee of a charity is not a |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|---|---|----------------|-------------------|-----------------|---|
| | | | | | | | conflict with development of the guideline. |
| Marcus Drake | Committee member | Non-financial professional and personal | Board member of the European Society of Female and Functional Urology | 2022 | November 2022 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead and NICE at recruitment.</p> <p>Rationale: Does not require withdrawing from the committee</p> |
| Marcus Drake | Committee member | Non-financial professional and personal | PREMISE trial. Ongoing trial investigating prostate resection versus minimally invasive surgery for bladder outlet obstruction due to enlarged prostate in the NHS. NIHR funded. End Date: February 2028. | April 2022 | February 2023 | Ongoing | <p>Declare and Participate</p> <p>Agreed by: Guideline lead in February 2023</p> <p>Rationale: Ongoing trial unlikely to</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|---|--|----------------|-------------------|-----------------|--|
| | | | | | | | report in lifetime of guideline. |
| Marcus Drake | Committee member | Non-financial professional and personal | UPSTREAM trial publication investigating urodynamics tests: Lewis AL, Young GJ, Selman LE, Rice C, Clement C, Ochieng CA, Abrams P, Blair P S, Chapple C, Glazener C M, Horwood J, McGrath J S, Noble S, Taylor G T, Lane J A & Drake MJ (2020). Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT. Health Technol Assess 24: 1-122. | 2020 | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Will not be able to make recommendations relating to urodynamics tests, should this arise. However, as member has particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|---|---|----------------|-------------------|-----------------|--|
| Marcus Drake | Committee member | Non-financial professional and personal | BESIDE trial publication investigating mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients, Astellas was the funder and sponsor of the study: Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambroner J, Mitcheson D, et al. (2016). Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol 70: 136-145. | 2016 | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: May need to withdraw from making recommendations if Astellas products considered for inclusion, if that arises.</p> |
| Marcus Drake | Committee member | Non-financial professional and personal | Publication on benefits of Phosphodiesterase Type 5 Inhibitors in LUTS: Drake MJ (2016). Do the Benefits of Phosphodiesterase Type 5 Inhibitors in Male Lower Urinary Tract Symptoms Go Beyond | 2016 | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|---|--|----------------|-------------------|-----------------|--|
| | | | Improved Symptoms? Eur Urol 70: 134-135. | | | | Rationale: Does not require withdrawing from the committee. Publication is an editorial relating to another article in the same journal issue. Publication would not be included as evidence in relevant review. |
| Marcus Drake | Committee member | Non-financial professional and personal | MASTER trial publication investigating slings: Constable L, Abrams P, Cooper D, Kilonzo M, Cotterill N, Harding C, Drake MJ, Pardoe MN, McDonald A, Smith R, Norrie J, McCormack K, Ramsay C, Uren A, Mundy T, Glazener C, MacLennan G. Synthetic sling or artificial urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER | 2022 | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in February 2023. Rationale: Will not be able to make recommendations relating to sling surgery, should this arise. However, as member has |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|---|---|----------------|-------------------|-----------------|---|
| | | | non-inferiority RCT. Health Technol Assess. 2022 Aug;26(36):1-152. doi: 10.3310/TBFZ0277. | | | | particular expertise in this area that would otherwise not be available to the committee, they may attend relevant meeting to answer specific questions relating to this. |
| Marcus Drake | Committee member | Non-financial professional and personal | STRIPE trial. Ongoing trial investigating tibial nerve stimulation: Smith MD, Tenison E, Drake MJ, Ben-Shlomo Y, Henderson EJ. Stimulation of the Tibial nerve Repetitively to Improve Incontinence in Parkinson's Electronically (STRIPE trial): a randomised control trial of tibial nerve stimulation for bladder symptoms in Parkinson's disease using a self-contained wearable device Trials. 2022 Oct 28;23(1):912. doi: 10.1186/s13063-022-06827-3. | 2022 | February 2023 | Ongoing | Declare and participate. Agreed by: Guideline lead in March 2023. Rationale: Ongoing trial unlikely to report in lifetime of guideline. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------|------------------|-------------------|---|----------------|-------------------|-----------------|--|
| Marcus Drake | Committee member | Indirect interest | Wife is Director of Dr MJ Drake limited | 2022 | February 2023 | Ongoing | <p>Declare and participate.</p> <p>Agreed by: Guideline lead in February 2023.</p> <p>Rationale: Does not require withdrawing from the committee</p> |
| | | | | | | | |
| | | | | | | | |

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.